# postMONARCH (NCT05169567)

> Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05169567
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Neoplasm; Neoplasm Metastasis
- Interventions: Abemaciclib; Fulvestrant; Placebo
- Enrollment: 368
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- YouTube: 104
- Podcasts: 74
- X threads: 46
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=postmonarch-nct05169567

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05169567", "email": "<work email>"}; the inbox owner confirms by the emailed link.